The essential transcriptional function of BRD4 in acute myeloid leukemia

Jae Seok Roe, Christopher R. Vakoc

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is often initiated by genetic alterations of machineries that regulate chromatin and transcription, thereby blocking cell differentiation. Such mechanisms may also render leukemia cells vulnerable to perturbations of transcriptional regulators, which includes small molecules targeting the coactivator protein BRD4. Numerous studies have validated BRD4 as a therapeutic target in diverse subtypes of AML; however, the vital function of BRD4 in this disease is only beginning to be understood. Here we discuss the recent progress in elucidating the transcriptional function of BRD4 in AML cells, with an emphasis on the desirable attributes, but also the inherent limitations, of targeting general coactivator proteins as cancer therapy.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalCold Spring Harbor Symposia on Quantitative Biology
Volume81
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Acute Myeloid Leukemia
Transcription
Chromatin
Proteins
Protein Transport
Myeloid Cells
Molecules
Cell Differentiation
Leukemia
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

@article{ff0b8a3995ce4f68824cc6121b7c9ac9,
title = "The essential transcriptional function of BRD4 in acute myeloid leukemia",
abstract = "Acute myeloid leukemia (AML) is often initiated by genetic alterations of machineries that regulate chromatin and transcription, thereby blocking cell differentiation. Such mechanisms may also render leukemia cells vulnerable to perturbations of transcriptional regulators, which includes small molecules targeting the coactivator protein BRD4. Numerous studies have validated BRD4 as a therapeutic target in diverse subtypes of AML; however, the vital function of BRD4 in this disease is only beginning to be understood. Here we discuss the recent progress in elucidating the transcriptional function of BRD4 in AML cells, with an emphasis on the desirable attributes, but also the inherent limitations, of targeting general coactivator proteins as cancer therapy.",
author = "Roe, {Jae Seok} and Vakoc, {Christopher R.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1101/sqb.2016.81.031039",
language = "English",
volume = "81",
pages = "61--66",
journal = "Cold Spring Harbor Symposia on Quantitative Biology",
issn = "0091-7451",
publisher = "Cold Spring Harbor Laboratory Press",
number = "1",

}

The essential transcriptional function of BRD4 in acute myeloid leukemia. / Roe, Jae Seok; Vakoc, Christopher R.

In: Cold Spring Harbor Symposia on Quantitative Biology, Vol. 81, No. 1, 01.01.2016, p. 61-66.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The essential transcriptional function of BRD4 in acute myeloid leukemia

AU - Roe, Jae Seok

AU - Vakoc, Christopher R.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Acute myeloid leukemia (AML) is often initiated by genetic alterations of machineries that regulate chromatin and transcription, thereby blocking cell differentiation. Such mechanisms may also render leukemia cells vulnerable to perturbations of transcriptional regulators, which includes small molecules targeting the coactivator protein BRD4. Numerous studies have validated BRD4 as a therapeutic target in diverse subtypes of AML; however, the vital function of BRD4 in this disease is only beginning to be understood. Here we discuss the recent progress in elucidating the transcriptional function of BRD4 in AML cells, with an emphasis on the desirable attributes, but also the inherent limitations, of targeting general coactivator proteins as cancer therapy.

AB - Acute myeloid leukemia (AML) is often initiated by genetic alterations of machineries that regulate chromatin and transcription, thereby blocking cell differentiation. Such mechanisms may also render leukemia cells vulnerable to perturbations of transcriptional regulators, which includes small molecules targeting the coactivator protein BRD4. Numerous studies have validated BRD4 as a therapeutic target in diverse subtypes of AML; however, the vital function of BRD4 in this disease is only beginning to be understood. Here we discuss the recent progress in elucidating the transcriptional function of BRD4 in AML cells, with an emphasis on the desirable attributes, but also the inherent limitations, of targeting general coactivator proteins as cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=85020998278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020998278&partnerID=8YFLogxK

U2 - 10.1101/sqb.2016.81.031039

DO - 10.1101/sqb.2016.81.031039

M3 - Article

C2 - 28174254

AN - SCOPUS:85020998278

VL - 81

SP - 61

EP - 66

JO - Cold Spring Harbor Symposia on Quantitative Biology

JF - Cold Spring Harbor Symposia on Quantitative Biology

SN - 0091-7451

IS - 1

ER -